A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Inclusion criteria

• Non-smoking Japanese males aged 20 to 44 years at the time of written, informed consent
• Body Mass Index (BMI) at screening is 18.5 or more but less than 25.0 kilogram per square metre (kg/m^2)
• Written, informed consent to participate in the study based on the participant's own free will
• Willing and able to comply with the requirements in the study after being fully informed of the requirements

Exclusion criteria

• Male participants with reproductive potential who and whose partner do not agree to practice medically appropriate contraception (Note: throughout the study)
• A history or complication of malignant tumor, lymphoma, leukemia, or lymphoproliferative disorder, a clinically significant disease requiring treatments within 8 weeks before the investigational product treatment, or a history of a clinically significant infection within 4 weeks before the investigational product treatment
• With a psychiatric, digestive, hepatic, renal, respiratory, endocrine, hematologic, neural, or cardiovascular disease within 4 weeks before the investigational product treatment, a congenital metabolic abnormality, or otherwise a disease that may affect the drug assessments
• With a surgical history (e.g., resection of the liver, kidney, or digestive tract, etc.) at screening that may affect the pharmacokinetics of the investigational product
• Suspicion of having a clinically abnormal symptom or an organ impairment that requires treatments based on the history/complications at screening or physical findings, vital signs, electrocardiogram findings, or laboratory values at screening or baseline
• Testing positive for human immunodeficiency virus (HIV) at screening
• A positive response to a qualitative test for hepatitis B virus surface antigen (HBs antigen), hepatitis B virus core antigen (HBc) antibody, hepatitis C virus (HCV) antibody, or syphilis
• Use of a prescription drug within 4 weeks before the investigational product treatment
• Use of an over-the-counter drug within 2 weeks before the investigational product treatment
• Receiving a vaccine within 4 weeks before the investigational product treatment
• Ongoing participation in another clinical study or use of an investigational product or device within 16 weeks before the investigational product treatment while participating in another clinical study
• Receiving blood transfusion within 12 weeks before the investigational product treatment, providing a whole-blood sample of 400 millilitre (mL) or more between 12 to 4 weeks before the investigational product treatment or a whole-blood sample of 200 mL or more within 4 weeks before the investigational product treatment, or giving blood components by pheresis within 2 weeks before the investigational product treatment